Answers are grounded in this paper and cite their sources.
• Amivantamab plus EGFR TKI lazertinib is now approved for EGFR mutated NSCLC • Thrombotic complications have been reported on amivantamab-lazertinib combinations • Osimertinib has been substituted for lazertinib in clinical practice • We report cases of venous and arterial thrombosis with amivantamab-osimertinib • A prophylaxis strategy for thrombotic prevention is discussed The bispecific antibody amivantamab has evidence in multiple combinations and indications for treating advanced Epidermal Growth Factor Receptor (EGFR) mutated NSCLC, including a recently approved first line combination with the third-generation EGFR tyrosine kinase inhibitor (TKI) lazertinib. Thrombotic complications have been reported at elevated rates for amivantamab-lazertinib combinations in clinical trials. While awaiting lazertinib approval, the previously established third-generation EGFR TKI osimertinib has been utilized by some clinicians in combinations with amivantamab, and this substitution will likely continue to be used in certain clinical contexts. Whether osimertinib-amivantamab combinations also carry thrombotic risk has not been described. Here, we outline three patient cases from our institution where osimertinib-amivantamab combinations were employed, highlighting early development of venous thromboembolism, arterial thrombosis, and use of anticoagulation prophylaxis. We review these cases in the context of the existing literature exploring thrombotic complications with amivantamab combinations. Clinicians should be aware of, discuss with patients, and take steps to mitigate, thrombotic risk with amivantamab-EGFR TKI combination therapy.
No takes yet. Share an insight, caveat, or question.
Watson et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: